Leukemia, Myelogenous, Chronic, BCR-ABL Positive

"Leukemia, Myelogenous, Chronic, BCR-ABL Positive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Descriptor ID	D015464
MeSH Number(s)	C04.557.337.539.250 C15.378.190.636.370
Concept/Terms	Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Granulocytic, Chronic Leukemia, Myelocytic, Chronic Leukemia, Myelogenous, Chronic Leukemia, Myelogenous, Ph1 Positive Leukemia, Myelogenous, Ph1-Positive Leukemia, Myeloid, Chronic Leukemia, Myeloid, Ph1 Positive Leukemia, Myeloid, Ph1-Positive Leukemia, Myeloid, Philadelphia Positive Leukemia, Myeloid, Philadelphia-Positive Myelocytic Leukemia, Chronic Chronic Myelocytic Leukemia Chronic Myelocytic Leukemias Leukemia, Chronic Myelocytic Leukemias, Chronic Myelocytic Myelocytic Leukemias, Chronic Myelogenous Leukemia, Chronic Chronic Myelogenous Leukemia Chronic Myelogenous Leukemias Leukemias, Chronic Myelogenous Myelogenous Leukemias, Chronic Myelogenous Leukemia, Ph1-Positive Leukemia, Ph1-Positive Myelogenous Leukemias, Ph1-Positive Myelogenous Myelogenous Leukemia, Ph1 Positive Myelogenous Leukemias, Ph1-Positive Ph1-Positive Myelogenous Leukemia Ph1-Positive Myelogenous Leukemias Myeloid Leukemia, Chronic Chronic Myeloid Leukemia Chronic Myeloid Leukemias Leukemias, Chronic Myeloid Myeloid Leukemias, Chronic Myeloid Leukemia, Ph1-Positive Leukemia, Ph1-Positive Myeloid Leukemias, Ph1-Positive Myeloid Myeloid Leukemia, Ph1 Positive Myeloid Leukemias, Ph1-Positive Ph1-Positive Myeloid Leukemia Ph1-Positive Myeloid Leukemias Myeloid Leukemia, Philadelphia-Positive Leukemia, Philadelphia-Positive Myeloid Leukemias, Philadelphia-Positive Myeloid Myeloid Leukemia, Philadelphia Positive Myeloid Leukemias, Philadelphia-Positive Philadelphia-Positive Myeloid Leukemia Philadelphia-Positive Myeloid Leukemias Granulocytic Leukemia, Chronic Chronic Granulocytic Leukemia Chronic Granulocytic Leukemias Granulocytic Leukemias, Chronic Leukemia, Chronic Granulocytic Leukemias, Chronic Granulocytic

Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelogenous, Chronic, BCR-ABL Positive".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Leukemia [C04.557.337]
Leukemia, Myeloid [C04.557.337.539]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C04.557.337.539.250]
Hemic and Lymphatic Diseases [C15]
Hematologic Diseases [C15.378]
Bone Marrow Diseases [C15.378.190]
Myeloproliferative Disorders [C15.378.190.636]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C15.378.190.636.370]

Below are MeSH descriptors whose meaning is related to "Leukemia, Myelogenous, Chronic, BCR-ABL Positive".

Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelogenous, Chronic, BCR-ABL Positive".

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blast Crisis
Leukemia, Myeloid, Accelerated Phase
Leukemia, Myeloid, Chronic-Phase

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" by people in this website by year, and whether "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" was a major or minor topic of these publications.

Bar chart showing 41 publications over 20 distinct years, with a maximum of 5 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1997	1	0	1
2001	0	1	1
2002	4	0	4
2003	1	1	2
2004	2	0	2
2005	2	0	2
2006	1	1	2
2007	3	0	3
2008	2	3	5
2009	3	0	3
2010	1	1	2
2011	2	0	2
2014	2	0	2
2015	2	0	2
2016	1	0	1
2017	1	0	1
2018	2	0	2
2020	1	0	1
2021	2	0	2

Below are the most recent publications written about "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" by people in Profiles.

Conti RM, Padula WV, Becker RV, Salamone S. The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia. J Manag Care Spec Pharm. 2021 Aug; 27(8):1077-1085.

View in: PubMed
Ploysangam P, Reynolds AL. Iris Infiltration as a Sign of Relapse in a Child with Chronic Myeloid Leukemia. Ophthalmology. 2021 05; 128(5):780.

View in: PubMed
Swaminathan N, Gupta S, Dourado C. Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient. F1000Res. 2020; 9:488.

View in: PubMed
Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Polakova KM. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Haematologica. 2018 12; 103(12):2016-2025.

View in: PubMed
Abuelgasim KA, Rehan H, Alsubaie M, Al Atwi N, Al Balwi M, Alshieban S, Almughairi A. Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature. J Med Case Rep. 2018 Mar 11; 12(1):64.

View in: PubMed
Perrotti D, Silvestri G, Stramucci L, Yu J, Trotta R. Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay. Curr Drug Targets. 2017; 18(4):377-388.

View in: PubMed
Hadley C, Wowkanech C, Eck B, Austin L, Sankar W, Tjoumakaris F. Morel-Lavall?e Lesion: Presenting Etiology of Chronic Myelogenous Leukemia in an Adolescent Athlete: A Case Report. JBJS Case Connect. 2016 Oct-Dec; 6(4):e99.

View in: PubMed
Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):47-53.

View in: PubMed
Ciarcia R, Damiano S, Puzio MV, Montagnaro S, Pagnini F, Pacilio C, Caparrotti G, Bellan C, Garofano T, Polito MS, Giordano A, Florio S. Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia. J Cell Physiol. 2016 Mar; 231(3):680-7.

View in: PubMed
Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Feb; 21(2):266-74.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement